Nivolumab联合ipilimumab：一种有希望的肝细胞癌一线治疗方法。

IF 11.8 Q1 MEDICINE, RESEARCH & EXPERIMENTAL

Med Pub Date : 2025-08-08 DOI:10.1016/j.medj.2025.100783

Bernardo Stefanini, Fabio Piscaglia

引用次数: 0

摘要

CheckMate 9DW最近发表在《柳叶刀》上，评估了双免疫检查点阻断nivolumab加ipilimumab （Nivo/Ipi）在治疗初治不可切除肝细胞癌患者中的疗效和安全性，并与索拉非尼或lenvatinib进行了比较。这项开放标签、随机的3期试验表明，Nivo/Ipi与lenvatinib或sorafenib相比，提供了总体生存获益。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

Nivolumab plus ipilimumab: A promising first-line therapy for hepatocellular carcinoma.

Recently published in The Lancet, CheckMate 9DW evaluated the efficacy and safety of dual immune checkpoint blockade nivolumab plus ipilimumab (Nivo/Ipi) compared to either sorafenib or lenvatinib in treatment-naive patients with unresectable hepatocellular carcinoma. This open-label, randomized phase 3 trial demonstrated that Nivo/Ipi provides an overall survival benefit versus lenvatinib or sorafenib.¹.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Med MEDICINE, RESEARCH & EXPERIMENTAL-

CiteScore

17.70

自引率

0.60%

发文量

102

期刊介绍： Med is a flagship medical journal published monthly by Cell Press, the global publisher of trusted and authoritative science journals including Cell, Cancer Cell, and Cell Reports Medicine. Our mission is to advance clinical research and practice by providing a communication forum for the publication of clinical trial results, innovative observations from longitudinal cohorts, and pioneering discoveries about disease mechanisms. The journal also encourages thought-leadership discussions among biomedical researchers, physicians, and other health scientists and stakeholders. Our goal is to improve health worldwide sustainably and ethically. Med publishes rigorously vetted original research and cutting-edge review and perspective articles on critical health issues globally and regionally. Our research section covers clinical case reports, first-in-human studies, large-scale clinical trials, population-based studies, as well as translational research work with the potential to change the course of medical research and improve clinical practice.